Chugai Pharmaceutical (OTCMKTS:CHGCY – Get Free Report) posted its quarterly earnings data on Tuesday. The company reported $0.27 earnings per share for the quarter, Zacks reports.
Chugai Pharmaceutical Stock Up 1.5%
Shares of CHGCY stock opened at $22.12 on Wednesday. Chugai Pharmaceutical has a fifty-two week low of $18.33 and a fifty-two week high of $34.84. The stock’s 50-day moving average is $20.77 and its two-hundred day moving average is $24.61.
Wall Street Analysts Forecast Growth
A number of analysts have recently issued reports on CHGCY shares. Nomura upgraded Chugai Pharmaceutical to a “hold” rating in a report on Tuesday, September 1st. UBS Group lowered Chugai Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 6th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy”.
About Chugai Pharmaceutical
Chugai Pharmaceutical Co, Ltd. is a Japan-based research-driven pharmaceutical company that develops, manufactures and markets prescription medicines. Its operations focus on addressing unmet medical needs through biotechnology, antibody engineering and other advanced drug-discovery technologies.
The company’s principal therapeutic areas include oncology, hematology, immunology, rheumatology, neuroscience, renal diseases and bone disorders. Its portfolio includes medicines such as Actemra (tocilizumab), used in several inflammatory conditions; Hemlibra (emicizumab), a treatment for hemophilia A; Alecensa (alectinib), an oncology medicine; and Enspryng (satralizumab), used for neuromyelitis optica spectrum disorder.
Founded in Japan in 1925, Chugai is headquartered in Tokyo and primarily serves the Japanese market while also commercializing products internationally through its strategic relationship with Roche.
Featured Stories
- Five stocks we like better than Chugai Pharmaceutical
- These 3 New ETFs Are Turning Heads—Are They Worth Buying?
- Coca-Cola Stock Is Everything AI Isn’t—And That’s Its Biggest Strength
- Apple’s Foldable iPhone Sold Out in Minutes, But Wall Street Has Questions
- Netflix Is Making Big Changes, But Can It Fix What’s Really Hurting Growth?
Receive News & Ratings for Chugai Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chugai Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
